Identification of Serum Biomarkers for Lung Cancer
The study is essential for the early detection of lung cancer (LC). Only 15% of LC cases are discovered while the tumor is in the early stages of development. Early detection of LC will likely have a major impact in the curative treatment route.
Dr. Sung Baek and fellow researchers from The Institute of Drug Development identified biomolecular indicators of disease, known as biomarkers, as it relates to lung cancer (LC) as well as asthma (AST). The materials and methods included the application of a multiplexed immunoassay for the identification of a panel of biomolecular indicators for the early detection of LC. The results show highly significant differences in serum levels of cytokines, growth factors, and biologically active peptides between LC patients and the healthy volunteers (control group). STUDY DETAILS
Researcher: Dr. Sung Baek, Dr. Elzbieta Izbicka, Dr. David Campos, Dr. Robert Streeper, and Dr. Armando Diaz III
Ask your most pressing medical and health questions at JBNI’s Team of Scientists and Physicians at http://jbni.us/forum or http://twitter.com/JBNIherbs. JBNI Genomics and Cancer Proteomics is the Maker of 100% Natural Bioprin. Bioprin is totally gentle on your stomach.